21407_Clinical Decision-Making in Narcolepsy Management: State Of The Art
Michael Thorpy, MD (Chair); Emmanuel Mignot, MD, PhD; Rafael Pelayo, MD; A. Thomas Perkins, MD, PhD. and Todd Swick, MD. review DSM-5 definitions, ICSD-3 guidelines, treatment options, and challenges in the management of narcolepsy in the pediatric population.
Narcolepsy is a disorder of the central nervous system that is described as a syndrome consisting of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hallucinations, automatic behaviors, and fragmented or disrupted sleep. If left untreated, narcoleptics risk falling asleep any time during the day, emphasizing the importance of controlling the condition for individuals who regularly operate dangerous machinery or rely on motor vehicles for regular transportation.
Furthermore, the increased risk of injury (falls or trauma), along with the intermittent nature of this disabling neurological condition, often leads to significant psychosocial impairment. Unfortunately, lifestyle changes are rarely sufficient to adequately control the symptoms of narcolepsy. Therefore, most patients require life-long medication to cope with the debilitating effects of the disorder. Since no cure for narcolepsy exists, non-pharmacologic and symptom-directed pharmacologic treatments are used together for optimal management of patients.
In this program, experts in narcolepsy management will describe the clinical features, best practices in diagnosis, narcolepsy definitions from the DSM-5 and newly released ICSD-3 guidelines, treatment options with associated clinical efficacy and safety data, and challenges in the pediatric population. In addition, case presentation and faculty panel discussion will help guide best practices in managing narcolepsy.